Originally published in Pharma’s Almanac The healthcare burden of cancer is increasing worldwide. There were an estimated 18 million new cancer cases in 2018,1 a 28% annual increase from 2012. Alarmingly, by 2030, annual diagnoses are expected to increase another 31%
Originally published in Pharma’s Almanac The biosimilars market in the United States continues to lag behind the rest of the world. However, there are promising signs that the market is poised to gain momentum. Expanding Biosimilars Market Given biologics’ complexity,
Chemspec Europe is an event that the Haig Barrett team looks forward to each year. With nearly 350 exhibitors from 27 countries, this gathering is a bellwether of sorts for the European specialty chemical industry. So what will we be
Haig Armaghanian Leads the Conversation with Synthetic Biology Executives Revolutionizing Therapeutic Development The therapeutic breakthroughs that are hitting the pages of scientific publications and news media outlets almost every day can make it feel as though this revolutionary medical progress
As the 2018 auto show season comes to a close, the Haig Barrett team and I are certain that profound service shifts in the automotive industry are not only coming; they are here. However, as we discussed the issue with
How advancements in biocatalytic capabilities have added to the API development and manufacturing toolbox Until recently, pharmaceutical active product ingredient (API) developers were limited to selecting from a roster of chemical catalysts to perform the transformations needed for drug manufacturing.
The synthetic biology field has the power to revolutionize many industries including chemicals, food, material science, molecular biology, pharmaceuticals, biotherapeutics, and many others. Synthetic biology has come a long way, and the very cost-effective ability to read and write DNA
The rapidly developing field of synthetic biology has the power to revolutionize many industries including chemicals, food, material science, molecular biology, pharmaceuticals, biotherapeutics, and many others. While numerous fields will and are benefiting from synthetic biology advancements, the medical and
by Haig Armaghanian As the new year begins, it’s helpful to look back at 2018 for clues as to what might be ahead. 2018 was a good year for biopharma. Profits were strong, IPO activity was robust, and Takeda’s $62
By Haig Armaghanian, Haig Barrett Management Consultants Given the dynamics of today’s business climate, it might come as no surprise that change management is a topic that emerges constantly as the Haig Barrett team and I interact with executives and